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The disposition of ceftriaxone was studied after a single 2 g intravenous dose in seven 
patients 3 to 5 days after liver transplantation. Ceftriaxone concentrations in plasma, 
urine, and bile were measured by HPLC, and plasma protein binding was determined by 
equilibrium dialysis. Plasma protein binding was nonlinear, and the unbound fraction 
varied between 0.05 and 0.56. Both capacity and ajfJnity were markedly different from 
reported values for normal subjects. The pharmacokinetic parameters obtained were: 
total body clearance (TBC), 11.2 ± 7.8 mL/hr/kg total and 44.8 ± 29.1 mL/hr/kg un-
bound; volume of distribution (Varea), 224 ± 76 mL/kg total and 767 ± 432 mL/kg un-
bound; steady-state volume of distribution (Vss )' 212 ± 68 mL/kg total and 651 ± 368 
mL/kg unbound; terminal disposition half-life (t 1/ 2 ), 21.6 ± 14.3 hour total and 16.3 ± 11.1 
hour unbound. TBC for both total and free drug was considerably lower than literature 
values for normal subjects. Varea for total drug was greater than normal, whereas the 
corresponding value for free drug was smaller than normal. The plasma ceftriaxone 
concentrations at 12 and 24 hours were above the reported minimum inhibitory concen-
tration (MIC). The fraction of the administered dose excreted in urine over 24 hours was 
38 ± 29% and did not differ markedly from that reported for normal subjects. Less than 
2')1, of the administered dose was excreted in 24-hour bile; however, biliary concentra-
tions were always above MIC. Ceftriaxone can be administered once or twice daily at a 
dose of 2 g/day for prophylaxis in liver transplant recipients. 
Ceftriaxone is a third-generation, parenteral ceph-
alosporin with broad-spectrum activity against 
gram-positive and gram-negative pathogens. 1 At the 
University of Pittsburgh, cefotaxime, another third-
generation cephalosporin, is currently used for pro-
phylaxis before and for 5 days after orthotopic liver 
transplantation. Ceftriaxone offers certain advan-
tages when compared with cefotaxime. First, cef-
triaxone has a half-life of 6 to 10 hours,2 and there-
fore, can be given less frequently than cefotaxime, 
which has a half-life of 1 to 2 hours. 3 Second, since 
liver transplant recipients are prone to infection of 
the biliary region, an antibiotic that maintains an 
adequate concentration in this area is desirable. As 
much as 40% of parent ceftriaxone is excreted into 
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the biliary tract,4 whereas cefotaxime is eliminated 
solely through the kidneys as the parent compound 
and as the metabolites. 3 Wider pathogenic spectrum 
is another advantage of ceftriaxone.1•5 Since a large 
fraction of the dose of ceftriaxone is excreted in the 
bile, the functional status of the liver is expected to 
influence the disposition of ceftriaxone. The objec-
tive of the present study was to elucidate ceftriaxone 
pharmacokinetics in orthotopic liver transplant pa-
tients, and subsequently determine an optimized 
dosing regimen in this patient population. 
MA TERIALS AND METHODS 
Subjects 
Seven adult orthotopic liver transplant patients, five 
men and two women, who were receiving intrave-
nous cefotaxime as part of their post-operative medi-
cation were randomly chosen to participate in the 
present study. Written informed consent was ob-
tained from all subjects. and the study protocol was 
approved by the University of Pittsburgh Institu-
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tiona I Review Board. Patients on any known enzyme 
inducers or inhibitors were excluded from the study. 
Study Design 
Three to 5 days after transplant, a 2 gram intrave-
nous dose of ceftriaxone was substituted for a single 
dose of cefotaxime. Ceftriaxone was given as an intra-
venous infusion over 15 minutes. Blood samples (2.5 
mL) were collected before and at 7, 15, and 30 min-
utes and 1, 2, 3, 4, 6, 8, 10, 12, 18, and 24 hours after 
the start of the infusion. Blood was centrifuged at 
room temperature, and the plasma was separated 
and frozen at -70°C until assayed. Urine (24 hr) and 
bile output were also collected via a catheter and a 
T-tube, respectively. These samples were measured, 
aliquoted, and frozen at -70°C until assayed. 
Assay 
Samples were processed by a modification of the 
method of Patel et a1. 6 The sample, 250 ~L of plasma, 
100 /-LL or urine, or 100 ~L of bile, was added to 0.75 
mL of wa ter; 2 mL of acetoni trile containing 5 /-Lg/ mL 
of medazepam, the internal standard, were added. 
After shaking for 10 minutes and centrifugation for 
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Figure I. Representative chromatograms that were obtained from 
s~biect "Ii: A, blank plasma; B. plasma 10 hr after drug administra· 
t~on. Pea!:" C and IS represent drug and internal standard, respec· 
lively; estJ.loted ceftriaxone concentration: 62 Itg/mL. 
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10 minutes at 1500 X g, 30 ~L of the supernatant were 
analyzed by HPLC. The chromatographic system 
consisted of a 150 X 4.6 mm 5~ C18 column (Supelco, 
Belfonte, PAl maintained at 40°C with ultraviolet 
detection at 254 nm. The mobile phase consisted of 
acetonitrile, 1% hexadecyltrimethylammonium 
bromide (HT AB) in water, 1M phosphate buffer pH 7 
and water (44:30:1:25). At a flow rate of 1.5 mL/min, 
the retention times of ceftriaxone and medazepam 
were 4.5 and 12 minutes, respectively (Figure 1). The 
standard curve was linear between 5 and 200 ~g/mL 
and the day-to-day coefficient of variation was 
<15%. 
Protein Binding 
Five plasma samples from each patient, representing 
approximately every other time point, were used to 
determine ceftriaxone plasma protein binding by 
equilibrium dialysis. Plasma (400 /-LL) was dialyzed 
against an equal volume of pH 7.4 isotonic phosphate 
buffer at 37°C. After a 4-hour equilibration time, the 
buffer and plasma were removed and assayed for 
ceftriaxone concentrations by HPLC as described ear-
lier. Preliminary studies indicated that equilibrium 
was achieved in 4 hours and that no volume shift 
correction was necessary. The percent of ceftriaxone 
bound to plasma proteins was determined by the fol-
lowing equation: 
% Bound = (Conc. in plasma 
- Conc. in buffer)/Conc. in plasma 
Data Analysis 
Plasma data of total ceftriaxone were analyzed by 
standard noncompartmental methods.7 Data from 
the protein-binding study were fitted using MINSQ 
least-square parameter estimating programS to the 
following equation9 : 
fJ = 1/(1 + Cu/nP + l/Ka • nP) 
where fJ is the ratio of bound to total plasma concen-
tra~ion, Cu is ~he unbound concentration in plasma, 
Ka is the affimty constant of the drug-protein inter-
action, and nP is the capacity constant. Using param-
eter estimates for each subject, the unbound concen-
tration corresponding to each time point was calcu-
lated using the following equation10: 
Cu = 0.5 {-(nP + Kd - Ctot ) 
+ [(nP + Kd - Ctot )2 + 4Kd· Ctot p/2} 
where Kd = l/Ka , Ctot is the total concentration in 
plasma. 
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TABLE I 
Biochemical Profile of Liver Transplant Patients* 
Age BW BUN SCr SGOT 
Pt. # Sex (yr) (kg) (mg%) (mg%) (U/L) 
1 M 57 83 24 1.1 270 
2 M 40 90 34 1.4 265 
3 M 50 69 58 2.7* 1022 
4 F 37 70 8 0.6 352 
5 M 58 70 37 1.3 119 
6 M 55 64 14 0.8 43 
7 F 55 79 51 2.6* 114 
Mean 50 75 32 1.5 312 
SD 8 9 18 0.8 331 
• Normal values: BUN. 7-22 mg%; Scr, 0.5-1.4 mg%; SGOT, 12-45 U/L; 
SGPT, 7-40 U/L; Bilirubin. 0.1-0.4 mg%/0.3-1.3 mg%; Alk phos. 37-107 U/L; 
Correlation among various pharmacokinetic pa-
rameters and biochemical indices of the patients was 
examined by linear regression. 1l 
RESULTS 
The characteristics of the patients who were partici-
pating in the present study are summariz"d in Table 
I. Two patients. 3 and 7. had markedly impaired 
renal function as determined by a serum creatinine 
level (Scr) >2 mg/ dl. Liver function in all the pa-
tients was below normal. as determined by various 
biochemical indices (Table I). Table II summarizes 
the pharmacokinetic parameters from plasma data; 
urine and bile data are shown in Table III. Table IV 
lists the correlations between the various pharmaco-
kinetic parameters and biochemical indices. 
Protein Binding 
Nonlinearity in the plasma protein binding of cef-
triaxone was evident throughout the concentration 
range attained in the present study: over the concen-
tration range of the samples measured. 13 to 243 p.g/ 
mL. the unbound fraction in plasma ranged from 
0.05 to 0.56. Capacity constant (nP) and affinity con-
stant (Ka) showed considerable variability among 
subjects (Table II). As shown in Table II. binding pa-
rameters are markedly different from those calcu-
lated for normal subjects.4 No significant correlation 
was found between binding parameters and albumin 
concentration (Table IV). 
Plasma 
Figures 2 and 3 show the plasma concentration-time 
profiles of total and unbound ceftriaxone in two pa-
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SGPT Bilirubint AP GGT Albumin TP 
(U/L) (mg%) (U/L) (U/L) (g%) (g%) 
434 0.8/1.4 69 44 2.0 4.1 
240 5.6/7.6 30 21 3.7 6.0 
856 2.6/3.3 51 62 2.9 5.2 
346 4.6/6.0 246 135 2.9 7.7 
60 11.5/13.0 508 511 2.6 5.1 
83 1.8/2.4 153 170 2.2 4.5 
138 1.6/2.2 56 56 2.9 5.3 
308 4.1/5.1 159 143 2.7 5.4 
278 3.7/4.1 171 171 0.6 1.2 
GGT, 8-69 U/L; Albumin. 3.5-4.8 g%; Total protein, 6.1-8.0 g% . 
t Direct/total. 
tients. The various pharmacokinetic parameters for 
total and unbound ceftriaxone are shown in Table II. 
Total body clearance (TBC) of total ceftriaxone was 
11.2 ± 7.8 mL/hr/kg. TBC for unbound drug was 
44.8 ± 29.1 mL/hr /kg. No significant correlation was 
found between TBe of either total or unbound drug 
and bilirubin levels (Table IV): only a slight trend of a 
negative relationship (P < .07) was found between 
the clearance of unbound drug and total bilirubin. 
The volume of distribution (Varea ) for total and un-
bound drug was 224 ± 76 mL/kg and 767 ± 432 mL/ 
kg. respectively. The steady-state volume of distri-
bution (V ss) was 212 ± 68 mL/kg for total ceftriaxone 
and 651 ± 368 mL/kg for the unbound drug in 
plasma. The volumes of distribution for total. but not 
unbound. ceftriaxone showed a significant positive 
correlation with bilirubin levels (Table IV). Terminal 
disposition rate constants (Table II) were 0.053 
± 0.039 hour-1 and 0.073 ± 0.055 hour- 1 for total and 
unbound ceftriaxone. respectively, and did not corre-
late significantly with bilirubin levels (Table IV). The 
terminal disposition plasma half-life was 21.6 ± 14.3 
hour for total and 16.3 ± 11.1 hour for unbound cef-
triaxone. The mean residence time (MRT) for total 
and unbound drug was 29.9 ± 20.6 hour and 21.3 
± 16.7 hour. respectively. 
Urine and Bile 
The percentage of dose that was excreted in urine 
over 24 hours (Table III) was 47.2 ± 29.6% and did not 
correlate significantly with Scr or BUN (Table IV). 
Estimated percent that was excreted in urine at time 
infinity was 68.3 ± 22.4% and correlated inversely 
with Scr and BUN (Table IV). Renal clearance, calcu-
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TABLE II 
Pharmacokinetics of Ceftriaxone in Liver Transplant Recipients 
Patient Number Mean ± SO 
2 3 4 5 6 7 Mean ± SO Normal Subjects· 
I. Protein Binding 
nP. mM x 10' 1.64 3.45 2.47 2.95 1.26 1.04 4.22 2.43 ± 1.19 4.33 ± 0.87 
Ka. mM-' x 10-' 5.92 1.74 5.90 1.76 1.48 9.83 0.56 3.89 ± 3.40 6.49 ± 1.15 
II. Total Drug 
Cm ... jlg/mL 290 218 306 315 245 560 293 318 ± 112 257 ± 17 
C'2' jlg/mL 61 84 90 33 48 54 117 70 ± 29 46 ± 7 
C2 •• jlg/mL 21 68 81 13 28 19 104 48 ± 36 15 ± 4 
TBC. mL/hr 994 368 311 1706 945 1059 260 806 ± 526 1190 ± 150 
mL/hr/kg 12.0 4.1 4.5 24.4 13.5 16.5 3.3 11.2 ± 7.8 
MRT. hr 12.5 58.8 44.6 8.5 25.8 10.7 48.5 299 ± 20.6 
V". L 12.4 21.7 13.9 14.5 24.4 11.4 12.6 15.8 ± 5.1 
mL/kg 150 241 201 207 349 178 159 212 ± 68 
V1Hn , L 13.1 20.9 16.3 14.7 26.7 12.7 12.1 16.6 ± 5.3 10.1 ± 1.0 
mL/kg 158 232 236 210 381 199 153 224 ± 76 
p. hr-' 0.076 0.018 0.019 0.116 0.035 0.083 0.021 0.053 ± 0;039 
t'/2' hr 9.2 39.4 36.3 6.0 19.6 8.3 32.4 13.1 • 5.8 (4.7-6.8); 
III. Unbound Drug 
Cm ... jlg/mL 187 70 154 157 178 492 140 197 ± 136 
C'2. jlg!mL 10 16 11 6 21 11 42 17 ± 12 
C2 •. jlg/mL 2 12 9 2 11 2 37 11 ± 12 
TBC. mL/hr 4322 2318 3085 7163 2245 2980 794 3272 ± 2019 14940 ± 2160 
mL/hr/kg 52.1 258 44.7 102.3 32.1 46.6 10.0 44.8 ± 29.1 
MRT. hr 6.6 44.9 25.0 6.2 21.0 4.7 40.7 21.3 ± 16.7 
V". l 28.6 104.1 77.2 44.3 47.2 14.0 32.3 49.7 ± 31.0 
mL/kg 345 1156 1119 634 674 218 409 651±368 
Varea • L 38.8 102.7 104.0 54.3 54.0 20.2 31.1 57.9 ± 33.3 162 ± 18 
ml/kg 467 1141 1507 776 771 315 394 767 ± 432 
ij • hr-' o 111 0023 0.030 0.132 0.042 0148 0.026 0.073 ± 0.055 
t'/2' hr 6.2 30.7 23.4 5.3 16.7 4.7 27.2 9.5t 7.6 
• Data for total ceftriaxone obtained from ref 6 (Patel): data for unbound t HarmonIC mean. 
ceftriaxone from ref 4. 1: Range in parentheses . 
. TABLE III 
Pharmacokinetics of Ceftriaxone in Liver Transplant Recipients 
Patient Number Mean ± SO 
2 3 4 5 6 7 Mean ± SO Normal Subjects· 
I. Urine 
% Exc, 24 hr 83.2 10.9 36.1 81.9 31.7 66.1 20.6 47.2 ± 29.6 42 ± 10 
CIR mL/hrt 975 133 217 1572 474 796 146 616 ± 534 533 ± 128 
CI R mL/hr/kgt 11.7 1.5 3.2 22.5 6.8 12.4 1.8 8.6 ± 7.6 
% Exc, intt 98.1 36.1 69.8 92.2 50.1 75.2 56.2 68.3 ± 22.4 
II. Bile 
Av Cone, j.Lg/mL 108 § 57 14 24 18 134 59 ± 51 
% Exc, 24 hr 1.21 0.55 0.13 0.25 0.26 1.74 0.69 ± 0.65 
Cle, mL/hrt 14.18 3.31 2.49 3.74 3.13 12.33 6.53 ± 1.35 
% Exc, int'i 1.43 1.06 0.15 0.40 0.30 4.75 1.35 ± 1.74 4011 
• Data from ref 6. § Bile not collected . 
t Calculated from 24 hr unne and plasma data. 
; Estimated from renal clearance and total body clearance 
I Estimated from biliary clearance and total body clearance. 
, Data from ref 2. 
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TABLE IV 
Correlations Between Pharmacokinetic Parameters and the Biochemical Indices of liver Transplant Recipients 
Bilirubin 
Unbound Total Albumin SCR BUN 
I. Binding Parameters 
nP, mM X 104 NS 
Ka, mM-1 X 10-4 NS 
II. Total Drug 
TBC, mL/hr NS NS 
mL/hr/kg NS NS 
d, hr- 1 NS NS 
V •• , L t 0.003 t 0.001 NS 
mL/kg t 0.0001 t 0.0001 NS 
Varea • L t 0.001 t 0.001 
mL/kg t 0.001 t 0.002 
III. Unbound Drug 
TBC. mL/hr NS NS 
mL/hr/kg NS NS 
d, hr- 1 NS NS 
% EXC 24 
CI R • mL/hr 
mL/hr/kg 
% EXC,"f 
lated from 24-hour urine and plasma data. was 8.6 
± 7.6 mL/hr/kg and correlated inversely with both 
Scr and BUN. 
The percentage of the dose excreted in bile over 24 
hour was 0.69% ± 0.65 (Table III) and did not corre-
late significantly with bilirubin levels (Table IV). 
Various pharmacokinetic parameters that were 
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Figure 2. Plosmo concentration-time proJile of total (e) and esti-
mated unbound (0) ceJtriaxone in a liver transplant recipient (#2) 
urter u 2 g dose gi\'en as a 15-min intravenous inJusion. 
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calculated in the present study were compared with 
corresponding literature values in healthy volun-
teers for total and unbound ceftriaxone (Tables II and 
III). For both total and unbound drug. TBe was lower 
in the liver transplant patients; the difference is 
more pronounced with respect to unbound as com-
pared with total drug. Varea for total ceftriaxone was 
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Figure 3. Plasma cancentration-time proJile oJ total (e) and esti-
mated unbound (0) ceftriaxone in a liver transplant recipient (#6) 
after a 2 g dose given as a I5-min intravenous infusion. 
CEFTRIAXONE IN LIVER-TRANSPLANT PATIENTS 
considerably greater. whereas that of unbound drug 
was smaller in the liver transplant recipients com-
pared with normal subjects. Plasma ceftriaxone con-
centrations after 12 hours (C12 ) and 24 hours (C 24 ) 
were considerably higher in this patient group as 
compared with normal subjects who were receiving 
the same dose of the drug. 
DISCUSSION 
Ceftriaxone offers certain practical advantages such 
as a longer half-life and higher biliary excretion as 
compared with cefotaxime. The present study deter-
mined whether ceftriaxone disposition in liver 
transplant recipients during the early post-operative 
period is different from its disposition in healthy 
subjects. and determined whether a 2 g/day dose 
will provide plasma ceftriaxone concentrations 
above the reported MIC. 
Ceftriaxone exhibits nonlinear kinetics and com-
parison of the parameters that were calculated in the 
present study for total drug with literature values in 
normal subjects was therefore confined to data from 
subjects who were receiving the same dose. i.e .. 2 g. 
Since binding is the only nonlinear process in cef-
triaxone disposition.4.8.12.13 the unbound drug is ex-
pected to behave linearly. and comparison was made 
among various reports regardless of the dose. 
Most of the pharmacokinetic parameters that were 
calculated in the present study were notably differ-
ent from literature values for normal subjects and 
exhibited much greater variability (Tables II and III). 
Such variability in kinetics may be related to the 
patient population that was studied. Even though 
Cmax observed in this study was comparable to that 
observed in normal subjects. much higher concen-
tration was maintained at 12 and 24 hours after drug 
administration (Table II). In all subjects. C24 was 
higher than the MIC50 of most susceptible organ-
isms. 14 The mean TBC of unbound ceftriaxone that 
was obtained in this study is approximately one fifth 
of the value reported for normal subjects (Table II). 
Such reduction could be explained on the basis of 
compromised liver function in the early post-opera-
tive period. Injury to the organ that was incurred by 
cold ischemia and warm reperfusion. resulting in an 
impairment of drug uptake by hepatocytes and of 
biliary excretion. may account for the reduction in 
the unbound clearance of ceftriaxone. In addition. 
four of the seven patients who were studied had a 
bilirubin concentration of greater than 2 mg/dL. 
Minor changes in the pharmacokinetic parameters of 
total ceftriaxone have been observed in patients 
ANTI-INFEC '.' 'E 
with liver disease15 and in patients with cholecystec-
tomy.16 
The volume of distribution of total drug is greater 
in patients than in normal subjects. whereas the op-
posite is observed with unbound volume of distribu-
tion (Table II). The larger volume of distribution is 
the result of decreased plasma protein binding due to 
decreased albumin concentration and decreased af-
finity of ceftriaxone for plasma proteins. In addition. 
the positive correlation that was obtained between 
the volume of distribution of total ceftriaxone and 
bilirubin. may indicate competition between with 
ceftriaxone and bilirubin for albumin binding sites. 
The reduction in unbound volume of distribution 
may be a reflection of the decrease in the uptake of 
ceftriaxone by body tissues. 
The half-life of ceftriaxone was significantly in-
creased in liver transplant patients. It was not possi-
ble to account for the dose that was administered by 
urinary and biliary excretion in 24 hours. The per-
centage of dose that was excreted in urine over 24 
hours did not differ from literature value for normal 
subjects who were receiving the same dose. whereas 
the percent that was excreted in bile was greatly re-
duced; however. such a comparison may be mislead-
ing because in normal subjects 24-hour urinary or 
biliary excretion approximates the total amount 
eliminated by the respective route. whereas in pa-
tients. in whom the terminal disposition half-life of 
ceftriaxone is markedly longer. the 24-hour urinary 
or biliary excretion is only a fraction of the total 
amount that is eliminated via each route. A better 
comparison may be made between the estimated 
percent that was excreted in urine or bile at time 
infinity in patients to the 24-hour urinary or biliary 
excretion in normal subjects (Table III). 
It could be inferred from the large fraction that was 
eliminated by urinary excretion and the small frac-
tion that was eliminated in bile that the kidneys con-
tribute more to the elimination of ceftriaxone in 
liver transplant recipients than in normal subjects. 
Although total 24-hour biliary recovery of ceftriax-
one (Table III) was markedly lower than that re-
ported in normal subjects.2 the pooled biliary con-
centration in all subjects (Table V) was higher than 
the MICso of most of the susceptible organisms. 14 
In conclusion. the disposition of ceftriaxone in 
liver transplant recipients in the early post-operative 
period is considerably different from normal sub-
jects. Clearance. binding. volume of distribution. 
and half-life are different from normal subjects. and 
lower doses of ceftriaxone may be sufficient to pre-
vent infection. Due to high variability in the clear-
ance. a minimum dose of 2 g/day is expected to 
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maintain adequate antibiotic concentrations in all 
patients, 
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